Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Nextech Venture

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 1
Average round size
info
The average size of a deal this fund participated in
$3M
Portfolio companies 1
Lead investments 0
Key employees Soon
Stages of investment
Late Stage Venture

Areas of investment

  • Biotechnology
  • Therapeutics
  • Life Science

Funds with similar focus

Funds from Switzerland
Funds with similar focus located in Switzerland:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AV Capital Austin, Texas, United States
Benslie International Ltd -
Big Loud Capital -
Groupe Arnault France, Ile-de-France, Paris
Guosheng-CLSA Investment Fund -
Huarun Runxiang Joint China, Fujian, Hunan
Iowa First Capital Fund Cedar Rapids, Iowa, United States
Keys Asset Management Luxembourg, Luxembourg
Maple Capital Advisors Delhi, India, New Delhi
Point Nine England, London, United Kingdom

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

ImVisioN Therapeutics

Biotechnology
Life Science
Therapeutics
$3M10 Sep 2008 Lower Saxony
News
Theseus Pharmaceuticals Raises $100M in Series B Funding

– Theseus Pharmaceuticals from Boston develops pan-variant kinase inhibitors to treat cancer.
– The company emerged from stealth with the close of a $100m Series B financing.
– The round was led by Foresite Capital with participation from Adage Capital Management, Boxer Capital, Farallon Capital Management, Longitude Capital, Nextech Ventures, Omega Healthcare Investors, Pontifax Venture Capital, Rock Springs Capital, and T. Rowe Price, as well as OrbiMed.
– In conjunction with the financing, Michael Rome, Ph.D., Managing Director of Foresite Capital, has joined the Theseus Board of Directors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Nextech Venture?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 1
Average round size 3M
Peak activity year 2008
Lead investments 0
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

ImVisioN Therapeutics

Biotechnology
Life Science
Therapeutics
$3M10 Sep 2008 Lower Saxony
Crunchbase icon

Content report

The following text will be sent to our editors: